Related Experiment Video
Updated: Jul 14, 2025
09:38
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
446
Sirolimus for Pediatric Cervicofacial Lymphatic Malformation: A Systematic Review and Meta-Analysis
Yasmine Kamhieh1, Robin Mitra2, Thomas Burnett3
1ENT Department Noah's Ark Children's Hospital, Cardiff, UK.
The Laryngoscope
|October 9, 2023
Summary
Sirolimus effectively reduces the size and improves symptoms of pediatric cervicofacial lymphatic malformations (LMs). Early treatment, especially before age two, shows better outcomes for these vascular anomalies.
Area of Science:
- Vascular Surgery
- Pediatric Oncology
- Pharmacology
Background:
- Pediatric cervicofacial lymphatic malformations (LMs) pose significant management challenges.
- Current treatment options for LMs have limitations in efficacy and safety.
- Sirolimus has emerged as a potential therapeutic agent for complex LMs.
Conclusions:
- Sirolimus demonstrates efficacy in managing pediatric head, neck, and airway lymphatic malformations.
- Further investigation through large, multi-center trials is warranted to define the role and limitations of sirolimus.
- Sirolimus represents a promising therapeutic option for pediatric LMs, particularly when initiated early.
